TG Therapeutics: Briumvi's Peak May Be Far Away (Rating Upgrade) (NASDAQ:TGTX)

seekingalpha.com · 2026-08-26

TG Therapeutics raised its Briumvi U.S. net product revenue from $885-$900 million to $890-$905 million. Read why TGTX stock is upgraded to a buy.

TickrTrends take: TG Therapeutics operates in the Healthcare sector where product lifecycle trajectories significantly influence long-term valuation outcomes. Given TickrTrends' current assessment of undervaluation, an analyst noting that Briumvi's peak sales potential may be distant suggests the market may not be fully pricing in the drug's extended revenue runway. Valuation-focused investors should monitor whether Briumvi adoption accelerates over coming quarters, as this would provide fundamental support for a sustained recovery in the company's valuation metrics.

Read the full story at seekingalpha.com →